BioNano Genomics, Inc. (NASDAQ: BNGO) reported Q4 revenue of $4 million versus the consensus estimate of $3.5 million.
2020 was an important momentum-building year for Bionano and one that allowed us to showcase many of our strengths. Despite 2020s challenges, we executed well on our commercial offerings for Saphyr® by expanding the number of systems in the field and the number of samples analyzed in our data services lab. We believe this... More